Healthy sight counseling: Diabetes and the eye

Clinical and Refractive Optometry

Volumn 20, Issue 11-12, 2009, Pages 248-258

  Stenson, Susan ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Transitions Optical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77249088748     PISSN: 17054850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published online ahead of print December 28, 2006]. Circulation 2007; 115: e69-el71.
2. National diabetes statistics. National Diabetes Information Clearinghouse Web site. http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Updated November 2005. Accessed April 16, 2008.
3. Hall CA, Jacques PF. Weighing in on the issues of type 2 diabetes in children: a review. Pediatr Phys Ther 2007; 19: 211-216.
4. Cara JF, Chaiken RL. Type 2 diabetes and the metabolic syndrome in children and adolescents. Curr Diab Rep 2006; 6: 241-250.
5. Centers for Disease Control and Prevention (CDC). Prevalence of visual impairment and selected eye diseases among persons aged ≥50 years with and without diabetes - United States, 2002. MMWR Morb Mortal Wkly Rep 2004; 53: 1069-1071.
6. Watkins PJ. Retinopathy. BMJ 2003; 326: 924-926.
7. Kashyap SR, Defronzo RA. The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res 2007; 4: 13-19.
8. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin 2007; 23: 905-917.
9. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823.
10. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999; 1(suppl 1): S1-S7.
11. Centers for Disease Control and Prevention (CDC). National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2005. http://www.cdc.gov/diabetes/pubs/pdf/ ndfs-2005.pdf. Accessed April 16, 2008.
12. Dzau V. The cardiovascular continuum and reninangiotensin-aldosterone system blockade. J Hypertens 2005; 23(suppl 1): S9-S17.
13. Rao SS, Disraeli P, McGregor T. Impaired glucose tolerance and impaired fasting glucose. Am Fam Physician 2004; 69: 1961-1968.
14. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.
15. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004; 88: 787-835, ix.
16. Kahn SE, Montgomery B, Howell W, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 5824-5829.
17. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297: 1568-1576.
18. De La Cruz JP, González-Correa JA, Guerrero A, de la Cuesta FS. Pharmacological approach to diabetic retinopathy. Diabetes Metab Res Rev 2004; 20: 91-113.
19. American Diabetes Association. Diabetes statistics. American Diabetes Association Web site. http://www.diabetes.org/diabetes-statistics. jsp. Accessed April 18, 2008.
20. Bloomgarden ZT. Screening for and managing diabetic retinopathy: current approaches. Am J Health Syst Pharm 2007; 64(17)(suppl 12): S8-S14.
21. Arden GB, Sidman RL, Arap W, Schlingemann RO. Spare the rod and spoil the eye. Br J Ophthalmol 2005; 89: 764-769.
22. Paques M, Massin P, Gaudric A. Growth factors and diabetic retinopathy. Diabetes Metab 1997; 23: 125-130.
23. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-2664.
24. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 2916-2924.
25. Yamagishi S, Nakamura K, Matsui T, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy [published online ahead of print October 10, 2005]. Med Hypotheses 2006; 66: 273-275.
26. Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy [published online ahead of print September 26, 2005]. Med Hypotheses 2006; 66: 1019-1021.
27. Yokoi M, Yamagishi SI, Takeuchi M, et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 2005; 89: 673-675.
28. Henricsson M, Nilsson A, Janzon L, Groop L. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 123-131.
29. Yam JC, Kwok AK. Update on the treatment of diabetic retinopathy. Hong Kong Med J 2007; 13: 46-60.
30. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 2004; 27: 540-2553.
31. Fong DS. Changing times for the management of diabetic retinopathy. Surv Ophthalmol 2002; 47(suppl 2): S238-S245.
32. Negi A, Vernon SA. An overview of the eye in diabetes. J R Soc Med 2003; 96: 266-272.
33. Klein BE, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. Am J Ophthalmol 1998; 126: 782-790.
34. Chiu CJ, Milton RC, Gensler G, Taylor A. Association between dietary glycemic index and age-related macular degeneration in nondiabetic participants in the Age-Related Eye Disease Study. Am J Clin Nutr 2007; 86: 180-188.
35. Oshitari T, Fujimoto N, Hanawa K, Adachi-Usami E, Roy S. Effect of chronic hyperglycemia on intraocular pressure in patients with diabetes [published online ahead of print October 17, 2006]. Am J Ophthalmol 2007; 143: 363-365.
36. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res 2007; 26: 470-485.
37. van Kuijk FJ. Effects of ultraviolet light on the eye: role of protective glasses. Environ Health Perspect 1991; 96: 177-184.
38. Dolin PJ, Johnson GJ. Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Ophthalmic Epidemiol 1994; 1: 155-164.
39. Roberts JE. Ocular phototoxicity. J Photochem Photobiol B 2001; 64(2-3): 136-143.
40. Robman L, Taylor H. External factors in the development of cataract. Eye 2005; 19: 1074-1082.
41. Vinson JA. Oxidative stress in cataracts. Pathophysiology 2006; 13: 151-162.
42. Young RW. The family of sunlight-related eye diseases. Optom Vis Sci 1994; 71: 125-144.
43. Mackie SW, Walsh G. Contrast and glare sensitivity in diabetic patients with and without pan-retinal photocoagulation. Ophthalmic Physiol Opt 1998; 18: 173-181.
44. Trick GL, Burde RM, Gordon MO, Santiago JV, Kilo C. The relationship between hue discrimination and contrast sensitivity deficits in patients with diabetes mellitus. Ophthalmology 1988; 95: 693-698.
45. Jaffe NS. Glare and contrast: indications for cataract surgery. J Cataract Refract Surg 1986; 12: 372-375.